本研究为期60周，主要疗效指标为哮喘症状。
The trial was conducted for 60 weeks, and the primary outcome was symptoms of asthma.
两项研究的主要疗效结果是反复出现静脉血栓栓塞。
The primary efficacy outcome for both studies was recurrent venous thromboembolism.
以汉密尔顿抑郁评定量表17项作为主要疗效评价指标。
The main efficacy measure was the change in total score of the Hamilton Depression Scale 17 item (HAMD17) from baseline to endpoint.
应用推荐